» Articles » PMID: 23389918

FISH Analysis for TET2 Deletion in a Cohort of 362 Brazilian Myeloid Malignancies: Correlation with Karyotype Abnormalities

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2013 Feb 8
PMID 23389918
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the prevalence of TET2 deletion by using a new FISH probe in a cohort of 362 Brazilian patients with myeloid neoplasms and their association with cytogenetic information (G-banding analysis). Normal karyotype was observed in 45.8 % of MDS (n = 44), 43.8 % of AML (n = 39) and 46.3 % of MPN (n = 82). Abnormalities of 4q24 (deletions, translocations or inversions) were associated with another chromosomal abnormality in four patients by G-banding analysis (2 MDS, 1 AML and 1 MPN). Interphase FISH analysis revealed deletion of TET2 in 21 patients (6 patients with abnormal karyotype and in 15 patients with normal karyotype). arrayCGH analysis revealed a cryptic deletion of the region 4q24 in all eight patients selected with myeloid malignancies (3 MDS, 1 AML and 4 MPN). Considering the significantly high cost of determining the mutational status of TET2 in patient samples by using conventional sequencing methods and sometimes the lack of regular use of SNP/aCGH array methodologies, FISH for the detection of TET2 abnormalities may become a potentially useful clinical tool. The search for alterations in TET2 gene may be important for the prediction of prognosis in normal/altered AML patients' karyotype or in the disease evolution of patients with MNP and MDS.

Citing Articles

A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera.

Kjeldsen E Cancers (Basel). 2018; 10(7).

PMID: 29941837 PMC: 6071118. DOI: 10.3390/cancers10070214.


TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population.

Yao H, Duan M, Lin L, Wu C, Fu X, Wang H Oncotarget. 2017; 8(11):18337-18347.

PMID: 28407691 PMC: 5392332. DOI: 10.18632/oncotarget.15440.

References
1.
Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C . Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009; 114(8):1628-32. DOI: 10.1182/blood-2009-01-197525. View

2.
Metzeler K, Maharry K, Radmacher M, Mrozek K, Margeson D, Becker H . TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29(10):1373-81. PMC: 3084003. DOI: 10.1200/JCO.2010.32.7742. View

3.
Pignataro D, Abdel-Wahab O . FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples. Leuk Res. 2011; 36(1):25-6. DOI: 10.1016/j.leukres.2011.08.018. View

4.
Zamora L, Xandri M, Garcia O, Marce S, Xicoy B, Granada I . Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. Am J Clin Pathol. 2012; 137(4):677-8. DOI: 10.1309/AJCP74TSVUHHAJFX. View

5.
Kohlmann A, Grossmann V, Klein H, Schindela S, Weiss T, Kazak B . Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010; 28(24):3858-65. DOI: 10.1200/JCO.2009.27.1361. View